Seewaldt and Buermeyer awarded grand prize from the Global Challenge to Prevent Breast Cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Victoria Seewaldt
Nancy Buermeyer
Michele Atlan

The Global Challenge to Prevent Breast Cancer has awarded:

  • The Grand Prize (Researcher Category) to Victoria Seewaldt, professor and chair of Population Sciences at City of Hope, who, with Chris Sistrunk of the SoCAL STEM and Community Outread Team, proposed STEM education to help prevent breast cancer.

  • The Grand Prize (Advocate Category) to Nancy Buermeyer, senior policy strategist at Breast Cancer Prevention Partners, who, with co-author Janet Nudelman, advocates reducing emissions at major ports to lower breast cancer risk.

  • In addition to the two Grand Prize winners chosen by a judging committee of experts and advocates, those in attendance and watching online also had their say, voting on an Audience Choice Award. The winner, Michele Atlan, vice president at the Breast Cancer Care and Research Fund, proposed a novel way to repackage natural ingredients to aid prevention efforts.

Started by the California Breast Cancer Research Program last fall, the Global Challenge was designed to uncover transformative prevention research ideas, and address the staggering statistic that, despite treatment advancements, people continue to be diagnosed with breast cancer at rates that have remained essentially unchanged over the past three decades.

Finalists were selected from dozens of applications that were submitted to the Global Challenge and competed at the Idea Showcase and Competition in San Francisco.

The ideas presented at the Global Challenge Idea Showcase and Competition will inform more than $15 million in funding that CBCRP will devote to breast cancer prevention research over the next five years.

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login